Showing posts with label Australia. Show all posts
Showing posts with label Australia. Show all posts

Sunday, February 5, 2017

PubMed Update December 2016 / January 2017

49 in two months. Enjoy!

Tomassoni AJ, Hawk KF, Jubanyik K, Nogee DP, Durant T, Lynch KL, Patel R, Dinh D, Ulrich A, D'Onofrio G.
MMWR Morb Mortal Wkly Rep. 2017 Feb 3;66(4):107-111. doi: 10.15585/mm6604a4.
Comments: Nice description of an outbreak of and public health response to insufflated fentanyl causing severe overdose.

Kobayashi L, Green TC, Bowman SE, Ray MC, McKenzie MS, Rich JD.
Simul Healthc. 2017 Feb;12(1):22-27. doi: 10.1097/SIH.0000000000000182.
Comments: Interesting and rigorous way to evaluate overdose knowledge after naloxone provision.

Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O.
Eur J Clin Pharmacol. 2017 Jan 31. doi: 10.1007/s00228-016-2191-1. [Epub ahead of print]
Comments: Data from another nasal naloxone in development.

Eggleston W, Clemency BM.
Clin Toxicol (Phila). 2017 Jan 31:1-3. doi: 10.1080/15563650.2017.1284336. [Epub ahead of print] No abstract available.
Comments: Authors note that data on the safety of discharging patients after an hour of observation may not apply in the current era of synthetic opioids.

Freeman PR, Goodin A, Troske S, Strahl A, Fallin A, Green TC.
J Am Pharm Assoc (2003). 2017 Jan 28. pii: S1544-3191(16)31004-4. doi: 10.1016/j.japh.2016.12.064. [Epub ahead of print]
Comments: Mixed opinions.

Lancaster K, Treloar C, Ritter A.
Health (London). 2017 Jan 1:1363459316688520. doi: 10.1177/1363459316688520. [Epub ahead of print]
Comments: Interesting article on whose knowledge matters.

Tuesday, December 6, 2016

PubMed Update October/November 2016

43 papers this round, and there are some goodies in here for sure (don't miss #38!). Given the number and varied issues addressed, I divided them up into topic areas and, given the number on naloxone, I divided up the naloxone topic areas as well.



Naloxone interventions


Primary care

Takeda MY, Katzman JG, Dole E, Bennett MH, Alchbli A, Duhigg D, Yonas H.
Subst Abus. 2016 Apr 19:1-6. [Epub ahead of print]
Comment: A pilot of naloxone co-prescribing.

Mueller SR, Koester S, Glanz JM, Gardner EM, Binswanger IA.
J Gen Intern Med. 2016 Oct 31. [Epub ahead of print]
Comment: Shows that naloxone for patients prescribed opioids must be appropriately framed.

Behar E, Rowe C, Santos GM, Coffa D, Turner C, Santos NC, Coffin PO.
J Gen Intern Med. 2016 Nov 4. [Epub ahead of print]
Comment: When actually implemented, providers really like adding naloxone to opioid-related care. One of five papers out of the Naloxone for Opioid Safety Evaluation of a naloxone co-prescribing study in San Francisco.


Tuesday, October 4, 2016

PubMed Update September 2016

15 papers this month.

Dodington J, Violano P, Baum CR, Bechtel K.
Pediatr Res. 2016 Sep 27. doi: 10.1038/pr.2016.193. [Epub ahead of print] Review.
Comment: Review of safety efforts in public health.

Behar E, Rowe C, Santos GM, Murphy S, Coffin PO.
Ann Fam Med. 2016 Sep;14(5):431-6. doi: 10.1370/afm.1972.
Comment: This is a partner paper to the study results reported a couple of months ago. Mixed methods interviews with 60 randomly selected patients on longterm opioid therapy for chronic pain who had been prescribed naloxone. The co-prescribing effort reached a population that was not really accessing naloxone through other community distribution sites in San Francisco. Some reported improved safety with opioids since receiving naloxone and none reported more high-risk use behaviors. About half of those who had overdosed denied “overdose” and described it as a bad reaction.

Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Petrush K, Berman S, Sigmon SC, Fingerhood M, Bigelow GE.
J Subst Abuse Treat. 2016 Dec;71:1-7.
Comment: Can’t access the paper, but the abstract suggests higher rates of overdose among rural drug users versus urban, while there were fewer overdose risk behaviors among rural users (potentially raising concerns about our risk behaviors, which were retrospectively developed).

Scott N, Carrotte ER, Higgs P, Cogger S, Stoové MA, Aitken CK, Dietze PM.
Drug Alcohol Depend. 2016 Sep 11;168:140-146. doi: 10.1016/j.drugalcdep.2016.08.638. [Epub ahead of print]
Comment: People who inject drugs have more psychological distress than the general population. Not surprised that intentional overdose (i.e. suicide attempt) is associated with psychological distress.

Klar SA, Brodkin E, Gibson E, Padhi S, Predy C, Green C, Lee V.
MMWR Morb Mortal Wkly Rep. 2016 Sep 23;65(37):1015-1016. doi: 10.15585/mmwr.mm6537a6.
Comment: Fentanyl in crack. Ugh.

Monday, August 8, 2016

PubMed Update July 2016

11 papers this month, including an announcement that naloxone is now over-the-counter in Australia.

Evans TI, Hadland SE, Clark MA, Green TC, Marshall BD.
Harm Reduct J. 2016 Jul 26;13(1):24. doi: 10.1186/s12954-016-0113-2.
Comments: Less than half knew about it.

Stein MD, Kanabar M, Anderson BJ, Lembke A, Bailey GL.
J Subst Abuse Treat. 2016 Sep;68:57-61. doi: 10.1016/j.jsat.2016.06.008. Epub 2016 Jun 16.
Comments: Important work, as there’s an effort to also reduce benzodiazepine prescribing among people who are on opioids. Understanding the drivers of BDZ use should be helpful in structuring interventions. Anxiety and managing opioid withdrawal were two main reasons.

Jones CM, Baldwin GT, Manocchio T, White JO, Mack KA.
MMWR Morb Mortal Wkly Rep. 2016 Jul 8;65(26):667-71. doi: 10.15585/mmwr.mm6526a2.
Comments: Interesting analysis of methadone prescribing, overdose, and diversion. It seems that efforts to reduce methadone, beginning in 2006, corresponded with reduced diversion and overdose; unfortunate that opioid overdose death overall continued to escalate.

Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL.
Drug Alcohol Depend. 2016 Aug 1;165:213-20. doi: 10.1016/j.drugalcdep.2016.06.011. Epub 2016 Jun 17.
Comments: Barriers to enrolling in agonist treatment in Ukraine.

Thursday, July 14, 2016

PubMed Update June 2016

Summer holiday. A mere 10 articles this month!

Nielsen S, Menon N, Larney S, Farrell M, Degenhardt L.
Addiction. 2016 Jul 1. doi: 10.1111/add.13517. [Epub ahead of print]
Comment: Most pharmacists in Australia would provide naloxone, but a minority feel comfortable selecting patients and educating about naloxone use and overdose.

Coffin PO, Behar E, Rowe C, Santos GM, Coffa D, Bald M, Vittinghoff E.
Ann Intern Med. 2016 Jun 28. doi: 10.7326/M15-2771. [Epub ahead of print]
Comment: Naloxone can be successfully prescribed to primary care patients on longterm opioids for chronic pain, and receipt of naloxone is associated with a remarkable reduction in opioid-related emergency department visits.

Sharma B, Bruner A, Barnett G, Fishman M.
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):473-87. doi: 10.1016/j.chc.2016.03.002. Epub 2016 Apr 9. Review.
Comment: Review of opioid use disorder and treatments.

Ambrose G, Amlani A, Buxton JA.
BMJ Open. 2016 Jun 21;6(6):e011224. doi: 10.1136/bmjopen-2016-011224.
Comment: Respondents administering naloxone to overdoses on the street were more likely to call for medical assistance than those doing so in a private residence. This makes a lot of sense. Imaging if giving a breathing treatment for asthma in a home versus on the street – the latter setting is more likely to result in seeking assistance.

Monday, May 9, 2016

PubMed Update April 2016

23 for this month! Lots of interesting stuff, from large-scale epidemiology to randomized controlled trials.

Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J.
J Clin Pharmacol. 2016 May 5. doi: 10.1002/jcph.759. [Epub ahead of print]
Comment: Details on the pharmacokinetics and usability studies for the new nasal device.

Madah-Amiri D, Clausen T.
Addiction. 2016 May 3. doi: 10.1111/add.13400. [Epub ahead of print] No abstract available.
Comment: Large-scale naloxone requires public health support.

Wilkerson RG, Kim HK, Windsor TA, Mareiniss DP.
Emerg Med Clin North Am. 2016 May;34(2):e1-e23. doi: 10.1016/j.emc.2015.11.002. Epub 2016 Feb 17. Review.
Comment: Focuses on risk factors for problematic opioid use and naloxone.

Wednesday, April 20, 2016

PubMed Update March 2016

23 this month.

McDonald R, Strang J.
Addiction. 2016 Mar 30. doi: 10.1111/add.13326. [Epub ahead of print] Review.
Comments: Take-home naloxone meets all Bradford Hill criteria for causality in reducing opioid overdose mortality. Incidence of fatality among overdoses in the setting of take-home naloxone was 0.8%.

Loreck D, Brandt NJ, DiPaula B.
J Gerontol Nurs. 2016 Apr 1;42(4):10-5. doi: 10.3928/00989134-20160314-04.
Comments: A review of the U.S. situation and treatments for opioid use disorder.

Darke S, Marel C, Mills KL, Ross J, Slade T, Tessson M.
Drug Alcohol Depend. 2016 May 1;162:206-10. doi: 10.1016/j.drugalcdep.2016.03.010. Epub 2016 Mar 18.
Comments: Heroin use is associated with 25-50 years of life lost. Over half of deaths and nearly two-thirds of years of life lost were due to opioid overdose.

Olsson MO, Bradvik L, Ă–jehagen A, Hakansson A.
Drug Alcohol Depend. 2016 May 1;162:176-81. doi: 10.1016/j.drugalcdep.2016.03.009. Epub 2016 Mar 17.
Comments: Accidental overdose death and suicide are distinct entities, with distinct predictive variables. This is important.

Saucier CD, Zaller N, Macmadu A, Green TC.
Drug Alcohol Depend. 2016 May 1;162:211-8. doi: 10.1016/j.drugalcdep.2016.03.011. Epub 2016 Mar 19.
Comments: Harm reduction programs training law enforcement, a critical step forward.

Tuesday, March 22, 2016

PubMed Update February 2016

Ten articles for February 2016.

[No authors listed]
ED Manag. 2016 Feb;28(2):13-9.
Comments: Review of the new CDC opioid prescribing guidelines.

Lenton SR, Dietze PM, Jauncey M.
Med J Aust. 2016 Mar 7;204(4):146-7. No abstract available.
Comments: Naloxone can now be over the counter in Australia, but there’s some work to be done in product design.

King R.
NASN Sch Nurse. 2016 Mar;31(2):96-101. doi: 10.1177/1942602X16628890.
Comments: Naloxone for school nurses in Delaware.

Agahi M, Shakoori V, Marashi SM.
Sultan Qaboos Univ Med J. 2016 Feb;16(1):e113-4. doi: 10.18295/squmj.2016.16.01.022. Epub 2016 Feb 2. No abstract available.
Comments: Long QT interval is a side effect of high methadone doses.

Wednesday, February 17, 2016

PubMed Update November 2015 - January 2016

We have 35 articles for your viewing this time, with apologies for the delay in getting this out. Thanks to Traci Green for offering to help out and for reviewing this post.


Becker WC, Merlin JS, Manhapra A, Edens EL.
Addict Sci Clin Pract. 2016 Jan 28;11(1):3. doi: 10.1186/s13722-016-0050-0.
Comment: Fascinating article. Worth a read if you’re interested in management of pain and opioids.

Harocopos A, Allen B, Paone D.
Int J Drug Policy. 2015 Dec 29. pii: S0955-3959(15)00374-6. doi: 10.1016/j.drugpo.2015.12.021. [Epub ahead of print]
Comment: Great to see some of the path from prescription opioids to heroin. Makes sense that first step is moving from a drug co-formulated with acetaminophen.

Samuels EA, Dwyer K, Mello MJ, Baird J, Kellogg A, Bernstein E.
Acad Emerg Med. 2016 Jan 27. doi: 10.1111/acem.12910. [Epub ahead of print]
Comment: To get EDs to enhance practices will require pressure from the top.

4) Internal Medicine Resident Knowledge, Attitudes and Barriers to Naloxone Prescription in Hospital and Clinic Settings.
Wilson JD, Spicyn N, Matson P, Alvanzo A, Feldman L.
Subst Abus. 2016 Jan 28:0. [Epub ahead of print]
Comment: Nice article from Baltimore finding that young physicians are ready and willing to prescribe naloxone, but aren’t routinely doing so yet.

Wednesday, August 12, 2015

PubMed Update June - July 2015

Great stuff this time! 34 in two months.


Wheeler E, Jones TS, Gilbert MK, Davidson PJ.
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):631-5.
Comment: The long-awaited sequel to 2010’s blockbuster naloxone MMWR report! 152,283 laypersons trained and 26,463 overdose reversals reported to naloxone programs through 2014.

Mars SG, Fessel JN, Bourgois P, Montero F, Karandinos G, Ciccarone D.
Soc Sci Med. 2015 Jun 30;140:44-53. doi: 10.1016/j.socscimed.2015.06.032. [Epub ahead of print]
Comment: Interesting use of qualitative data exploring the role of heroin markets on overdose risk, suggesting that factors such as open-air versus behind-closed-door markets can affect risk.

Cropsey KL, Stevens EN, Valera P, Brendan Clark C, Bulls HW, Nair P, Lane PS.
Drug Alcohol Depend. 2015 Jul 10. pii: S0376-8716(15)00352-X. doi: 10.1016/j.drugalcdep.2015.06.038. [Epub ahead of print]
Comment: There’s a movement toward not prescribing opioids with benzodiazepines at all. This makes some sense from an overdose prevention perspective, however the impact of such a policy is unknown. Those who require both opioids and benzodiazepines generally have far more complex and substantial mental health challenges. Just removing one or the other of the agents may results in worsening mental health or even increased rates of self-harm. Or not. Nobody knows.

Soukup-Baljak Y, Greer AM, Amlani A, Sampson O, Buxton JA.
Int J Drug Policy. 2015 Jul 2. pii: S0955-3959(15)00200-5. doi: 10.1016/j.drugpo.2015.06.006. [Epub ahead of print]
Comment: This is interesting, particularly in an era of frequent high-potency batches of heroin or even pure fentanyl derivatives. Subjects recommend using words like “dangerous” or “lethal” instead of “potent” which can be misconstrued as desirable. They also emphasized timeliness. As one of the first studies to really look at this issue, this paper is well worth the read.

Visconti AJ, Santos GM, Lemos NP, Burke C, Coffin PO.
J Urban Health. 2015 Jun 16. [Epub ahead of print]
Comment: Epidemiology of opioid overdose mortality in San Francisco – the first since Pete Davidson’s seminal geocoding paper in 2003 that led SF to refocus overdose prevention efforts to the hardest hit neighborhoods. This paper documents that heroin overdose is now remarkably rare in San Francisco, although for me it raises more questions than it answers.

Sunday, March 8, 2015

PubMed Update November 2014 - February 2015

Catching up on 51 papers in 4 months. Did you miss me?

Rech MA, Donahey E, Cappiello Dziedzic JM, Oh L, Greenhalgh E.
Pharmacotherapy. 2014 Dec 4. doi: 10.1002/phar.1522. [Epub ahead of print]
Comment: Review of management of drug toxicities among novel, synthetic compounds.

Ray B, O'Donnell D, Kahre K.
Drug Alcohol Depend. 2015 Jan 1;146:107-10. doi: 10.1016/j.drugalcdep.2014.10.026. Epub 2014 Nov 8.
Comment: Police officers like being trained to carry naloxone.

Robinson A, Wermeling DP.
Am J Health Syst Pharm. 2014 Dec 15;71(24):2129-35. doi: 10.2146/ajhp130798.
Comment: Review of intranasal naloxone for overdose reversal.

Dasgupta N, Creppage K, Austin A, Ringwalt C, Sanford C, Proescholdbell SK.
Drug Alcohol Depend. 2014 Dec 1;145:238-41. doi: 10.1016/j.drugalcdep.2014.10.005. Epub 2014 Oct 18.
Comment: Heroin overdoses are increasing.

Jones JD, Roux P, Stancliff S, Matthews W, Comer SD.
Int J Drug Policy. 2014 Jan;25(1):166-70. doi: 10.1016/j.drugpo.2013.05.006. Epub 2013 Jun 15.
Comment: Brief overdose training works for naloxone distribution. This is important because many places are requiring prolonged trainings that end up limiting access to those who are unable or unwilling to invest that degree of time.

Behar E, Santos GM, Wheeler E, Rowe C, Coffin PO.
Drug Alcohol Depend. 2015 Mar 1;148:209-12. doi: 10.1016/j.drugalcdep.2014.12.009. Epub 2014 Dec 19.
Comment: Again, brief overdose training works for naloxone distribution.

Sunday, November 16, 2014

PubMed Update August-October 2014

Three months. 32 articles. Enough said.

Darke S, Marel C, Mills KL, Ross J, Slade T, Burns L, Teesson M.
Drug Alcohol Depend. 2014 Sep 16. [Epub ahead of print]
Comment: This study (the ATOS) and the team of investigators have produced some of the most powerful and useful data in substance use research. Once again they have delved into heroin overdose by following treatment patients 11 years out. At least 10.2% of the cohort had died by that time and an additional 9.4% were unaccounted for. Among the 70.1% interviewed, 67.5% had overdosed, 24.4% had experienced five or more overdoses (again suggesting that there are “overdosers” out there who are at very elevated risk of the event). In the past year before the follow-up visit, 4.9% had overdosed (11.8% of those who had used heroin in that period), 95.2% of whom had overdosed previously. Those who overdosed were more likely to report higher levels of non-heroin opiate use, as well as benzodiazepine, cocaine, and methamphetamine use.

Simonson W.
Geriatr Nurs. 2014 Sep-Oct;35(5):381-2.
Comment: A review of the role of take-home naloxone in the form of the new autoinjector.

Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D, Davis JW, Dudek J, Eichler BA, Fernandes JC, Fondario A, Gabella B, Hume B, Huntamer T, Kariisa M, Largo TW, Miles J, Newmyer A, Nitcheva D, Perez BE, Proescholdbell SK, Sabel JC, Skiba J, Slavova S, Stone K, Tharp JM, Wendling T, Wright D, Zehner AM.
MMWR Morb Mortal Wkly Rep. 2014 Oct 3;63(39):849-54.
Comment: This report demonstrates declining prescription opioid deaths (-6.6%), but heroin deaths increased so much (+101.7%) that the data actually demonstrate an overall increase in opioid overdose mortality from 2010 to 2012 (+4.3%). There is disagreement as to what is driving the increase in heroin use and overdose. Is it an inevitable consequence of increased availability of opioids? Or is it the result of growing restrictions on access to those opioids? Clearly there are elements of both, leaving us with conflicting duties when it comes to managing those already reliant upon prescription opioids. Western medical ethics is clear on this point: our patient is the person we treat, who may have been harmed by the very same prescribing behavior we are now trying to change and who may be further harmed by those changes. If we truly believe that this epidemic is “iatrogenic” (i.e. caused by medical care, akin to a surgeon leaving scissors in an abdomen), then we have to be extremely cautious and thoughtful in fixing the problem and we can never abandon the patient.

Lenton S, Dietze P, Olsen A, Wiggins N, McDonald D, Fowlie C.
Drug Alcohol Rev. 2014 Oct 1. doi: 10.1111/dar.12198. [Epub ahead of print]
Comment: It's taken an incredibly long time for take-home naloxone to reach Australia, especially given how innovative that country has been with respect to managing drug policy and overdose.

Green TC, Bratberg J, Dauria EF, Rich JD.
R I Med J (2013). 2014 Oct 1;97(10):29-33.
Comment: The first of three articles in this post from Rhode Island, US, which has been facing a surge in opioid overdose deaths and has been responding with expanded naloxone treatment availability. This and the next two articles are free at: http://rimed.org/rimedicaljournal-2014-10.asp.

Tuesday, January 7, 2014

PubMed Update November/December 2013

We close out 2013 with an impressive 25 papers in the final two months for a total count of 89 papers. Some interesting new approaches and perspectives, including a paper on the underappreciated role of adulterants, a couple of naltrexone papers, and lots of lay naloxone.

Caulkins JP, Everingham S, Kilmer B, Midgette G.
Curr Drug Abuse Rev. 2013 Dec 5. [Epub ahead of print]
Comments: Somewhat surprising data suggesting relatively separate markets for heroin, cocaine and methamphetamine.

Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L.
Drug Alcohol Rev. 2013 Dec 3. doi: 10.1111/dar.12095. [Epub ahead of print]
Comments: A systematic review concluding that the data for naltrexone implants for opioid dependence are insufficient for use outside of clinical trials.

Bohnert AS, Ilgen MA, Trafton JA, Kerns RD, Eisenberg A, Ganoczy D, Blow FC.
Clin J Pain. 2013 Nov 25. [Epub ahead of print]
Comments: What happened with opioid analgesic overdose deaths in the United States also happened in among veterans receiving care in the Veterans’ Administration.

Coffin P, Banta-Green C.
Ann Intern Med. 2013 Dec 10. doi: 10.7326/M13-2781. [Epub ahead of print] No abstract available.
Comments: Commentary on the reliance on opioids and minimizing the potential harms of stewardship efforts.